We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

December 20, 2019

Looking Back to Move Forward - Our 2019 Digital Health Round Up

Commentary
Hanna Phelan
&

All cards on the table. In 2019 digital health did not fix healthcare. It's still clear that only a small part of the innovation healthcare needs is digital. Like any year, 2019 has had its peaks and troughs for digital health. Our take? We still have some way to go before we can claim that digital intervention has made healthcare substantially better - but we’re seeing progress. 

Looking back we saw some partnerships mature and flourish, others stumble and fall. We saw continued growth in the hive-mind understanding of digital health around some of the most promising use cases and regulators stepping up their game to facilitate change. There was also a growing presence of big tech moves (some more welcome than others) in addition to broadly increasing activity in mental health, digital therapeutics and social determinants of health. 

It’s important we pause and reflect on the 12 months of frenzied activity in order to step into 2020 well prepared - we want to hold that space for you. Here are some of our highlights from the year to set the scene before we share our perspective on the trends to come in January. 

Digital Health Collaborations & Partnerships 2019

Health innovation doesn’t happen in a vacuum (not the first or last time we’ll say this). In the past 12 months we have seen partnerships and collaborations diversify and mature across the sector, and others come to a pointed end. 

Collaborations and Partnerships at HealthXL 

This year at HealthXL we expanded our own partnerships with other industry leaders to accelerate understanding and action. One collaboration that gained particular attention was the recent coming together of the Digital Medicine Society (DIME), the Digital Therapeutics Alliance (DTA) and NODE Health to contribute to increased understanding of the vocabulary in the health innovation environment. As an extension of this mission to foster understanding and collaboration to help industry leaders and innovators navigate towards true outcome improvements, we also brought together some of the foremost leaders across the globe to share musings, skepticism and learnings at 8 HealthXL gatherings in Shanghai, Melbourne, Dublin, New York, Tokyo and Florida. Our 4 quarterly research reports also would not have been possible without the contribution of our expert community! 

Our HealthXL Research Deep Dives from 2019

In 2019 we were also delighted to deepen our collaboration with current customers while also forging new partnerships including dermatology focused Almirall with CDO Francesca Wuttke at the helm and UCB, a bio-pharmaceutical company focused on immunology and neurology. 

HealthXL expanded our footprint geographically with the launch of partnerships with Medibank, Australia's second largest payor and Monash University’s Turner Institute for Brain and Mental Health, one of Australia’s largest Institutes for brain and mental health.

We initiated a number of strategic research projects for clients such as EIT Health, a consortium of over 140 partners from leading businesses, research institutions with a goal to contribute to increasing the competitiveness of European industry, and ConvaTec, an international medical products and technologies company offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. 

Beyond health systems and pharma companies, we also started to work with agencies and consulting houses such as The Kinetix Group, ZS Associates and Evolution Road to support on their advising services around digital health in addition to deepening our work with startups bringing on Health Catalyst, Sleepscore Labs and Investors such as Livongo affiliates 7wire Ventures. 


Some of our new customers from 2019


Partnerships and Collaborations Further Afield

In the wider community numerous partners emerged that promised to tread new ground - some getting closer to delivering on expectations than others. 

DTX and Pharma: Sandoz and Pear Therapeutics’ relationship, which many enthusiastically lauded as a big deal for paving the way in an unprecedented space of DTx commercialization, came to a sudden halt. This U-turn of two of the first Software as a Medical Device (SaMD) approvals, reSET and reSET-O, gives us a reality check in terms of expectations and the multitude of variables at play in these previously unexplored partnership dynamics. 

In a more positive vein for DTx and Pharma, Sanofi and Happify announced their plan to submit their co-developed digital therapy to the FDA  for clearance as a medical device for MS patients. The good news is that people are taking mental and behavioural health aspects of disease more seriously and providing digital solutions that are better suited to managing the same. 

Biofourmis also recently announced that they will run trials with their pharma partner Novartis in the heart failure space. The acquisition of wearable Biovotion by Biofourmis also lends itself nicely to the testing and measurement of digital biomarkers in these trials. As an outcome, we can expect some much needed regulatory movements in the clinical trials and novel biomarkers avenue. 

The bottom line here? This is a marathon, not a sprint and while this particular partnership didn’t go to plan that’s not to say the DTx opportunity as a whole is degenerating - in fact 2019 DTx activity nods to the opposite as infrastructural partnerships develop (e.g. Express Scripts enabling clinicians to prescribe 15 vetted solutions including Propellor and Omada).

Big Tech Partnering for Data Access: There was recent uproar associated with Google’s partnership with US hospital network Ascension which provided the tech giant with access to millions of medical records unawares to patients and clinicians. This is a stark reminder of the gaping blind-spots still at play in digital health when it comes to privacy and regulation, the power and data hunger of big tech to get ahead of the curve, but also the growing focus that big tech is attributing to their place in healthcare e.g. Google’s acquisition of FitBit. After the activity this year from Big Tech, something tells us it’s just the beginning of the big tech foray into healthcare.  

We mapped the most promising companies over 23 digital health market segments - with more to come!


A Maturing Market? End of the IPO Drought, Investments & Acquisitions

This year saw the so called ‘Digital Health IPO Drought’ come to an end with some big ticket public offerings including Livongo, Health Catalyst and Phreesia in addition to some pretty sizable acquisitions such as Google/FitBit, Biofourmis/Biovotion, American Well/Aligned Telehealth (again another move for mental health) and Amazon’s second digital health acquisition of Health Navigator.

Investments and acquisitions were also put into question in 2019: 

While investments, acquisitions and IPOSs are important we acknowledge the need for data insights beyond this. n 2019, we enabled our customers to stay abreast of these changes with a collation of added data points for true context to guide their strategic navigation. 

Some quick stats on how we approached this below: 

With these data points centralised we want to help the community develop a more nuanced view of what success actually looks like for a digital health company.  

Growing Evidence and Regulatory Moves 

The call for evidence in digital health is growing louder. As a sector we are starting to get to grips with the types of evidence (both clinical and economic) that we should expect based on different therapeutic areas, risk levels and presence of unmet need. 

When we evaluated the past 5 years of digital health related publications (RCTs, feasibility studies and beyond), we noticed a considerable rise in those focused on cardiometabolic disorders, musculoskeletal disorders and neurology. There appears to be a clear alignment with these conditions and the opportunity for technology to address rare conditions with few pharmacological treatment options, conditions with low understanding of patient symptoms and QoL at home. 

One of the most recent and most exciting additions to HealthXL aims to address the ever expanding place of research and evidence. To kick off this unique research feature, we have added validated company research to 1000 company profiles within each of the 23 hand-selected HealthXL Segments with our sights firmly set on mapping the digital health universe in 2020. From opportunities in Pharma R&D to disease management, we have enriched hand selected solution profiles with investment information, partnership insights and now evidence to help our customers understand what companies have the most validation (clinical, economic, or other). 

Within this data we noticed there was a doubling down on Digital Therapeutic related publications from solutions looking to excel in the market and firmly align themselves with the agreed definition of DTx including the following: 

Working alongside the 2019 focus on evidence, global regulators and policy makers worked hard to reform systems and facilitate change:

So, what will the next decade of digital health hold? Proceed with Caution and Hope 

There are some interesting wheels in motion and great learning from both successes and failures that we have gained in the past 12-months. Watch this space for our January predictions of what this may mean for the key areas of activity in 2020. 

Thank you to all our members and subscribers worldwide - looking forward to working with you next year! We’ll continue to have our finger on the pulse of digital health going into the new decade and continue to respond with distilled insights via our data platform, events, blogs, podcast and research reports. Looking forward to seeing what 2020 has in store!

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

What are the best routes to market in DTx?

12th April @ 11:00am EDT

Join us as we discuss what are the most scalable and sustainable routes to market in DTx. Great opportunity to connect with peers and meet new people.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Masterclass - The regulation of DTx

15th April @ 10:30am EDT

Join us in this Masterclass led by Stephen Gibney from BlueBridge Technologies as we discuss the regulation of DTx. Great opportunity to Listen, engage and most importantly, enjoy.

Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Why is Medtech right for DTx and vice versa

22nd April @ 11:30am EDT

Join our Digital Health Meeting as we discuss why Medtech is right for DTx and vice versa. Apply promptly to get involved in the conversation, network with peers and share your thoughts on the topic.

Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Vivian Emmely de Ruijter
Vivian Emmely de Ruijter
Senior Manager, Digital and Technology Group, Manatt Ventures at Manatt, Phelps & Phillips, LLP
Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Vivian Emmely de Ruijter
Vivian Emmely de Ruijter
Senior Manager, Digital and Technology Group, Manatt Ventures at Manatt, Phelps & Phillips, LLP
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx - Overview of market and deals

28th April @ 10:30AM EDT

Join our Digital Health Meeting focused on the overview of market and deals in the DTx industry. Apply promptly to secure your place in the discussion and network with peers.

Featuring
Ethan Wergelis-Isaacson
Ethan Wergelis-Isaacson
Digital Health Strategy & Business Development , Otsuka Pharmaceutical Companies
Featuring
Ethan Wergelis-Isaacson
Ethan Wergelis-Isaacson
Digital Health Strategy & Business Development , Otsuka Pharmaceutical Companies

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

What are the best routes to market in DTx?

12th April @ 11:00am EDT

Join us as we discuss what are the most scalable and sustainable routes to market in DTx. Great opportunity to connect with peers and meet new people.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support

The future of digital medical education

13th April @ 10:30am EDT

Join us as we discuss the future of digital medical education and its impact on digital health adoption. Great opportunity to connect with peers, engage in thought-provoking conversations and meet new people.

Featuring
Joshua Landy MD
Joshua Landy MD
Chief Medical Officer, Figure 1
Meg Barron
Meg Barron
Vice President, Digital Health Strategy, American Medical Association
Featuring
Joshua Landy MD
Joshua Landy MD
Chief Medical Officer, Figure 1
Meg Barron
Meg Barron
Vice President, Digital Health Strategy, American Medical Association
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support

Role of digital patient communities in 2021

14th April @ 10:30am EDT

Join our Digital Health Meeting as we discuss the role of digital patient communities in 2021. Apply now to secure your place in the conversation and gain valuable insights from thought leaders in the industry.

Featuring
Chelsea Pan
Chelsea Pan
Partnership Engagement Manager, Verily Life Sciences
Carlos Rodarte
Carlos Rodarte
Founder & Managing Director, Volar Health LLC
Featuring
Chelsea Pan
Chelsea Pan
Partnership Engagement Manager, Verily Life Sciences
Carlos Rodarte
Carlos Rodarte
Founder & Managing Director, Volar Health LLC
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Masterclass - The regulation of DTx

15th April @ 10:30am EDT

Join us in this Masterclass led by Stephen Gibney from BlueBridge Technologies as we discuss the regulation of DTx. Great opportunity to Listen, engage and most importantly, enjoy.

Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.